SCHEMBL5260103

SCHEMBL5260103

COc1cc(Nc2nc(C)cc(C)n2)ccc1-c1nc2ccccc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.62
AURKA O14965 4/20 0.62
AURKB Q96GD4 3/20 0.62
TEK Q02763 5/20 0.59
KDR P35968 4/20 0.59
FLT4 P35916 3/20 0.59
ERBB2 P04626 3/20 0.59
IGF1R P08069 2/20 0.59
SRC P12931 1/20 0.59
MAPT P10636 5/20 0.58
MEN1 O00255 3/20 0.58
ALDH1A1 P00352 3/20 0.58
KMT2A Q03164 3/20 0.58
KDM4E B2RXH2 2/20 0.58
HCRTR1 O43613 1/20 0.58
GLA P06280 1/20 0.58
GAA P10253 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5259792 0.85 MAPT (0.58) EGFRAURKAAURKBKDRMAPT
SCHEMBL4604363 0.83 MAPT (0.67) EGFRAURKAAURKBTEKKDR
SCHEMBL5262961 0.83 EGFR (0.63) EGFRAURKAAURKBTEKKDR
SCHEMBL5259019 0.81 MAPT (0.64) EGFRAURKBTEKKDRFLT4
SCHEMBL5263632 0.79 APP (0.63) EGFRAURKAAURKBKDRFLT4
SCHEMBL5259397 0.77 SMN1; SMN2 (0.60) EGFRAURKAAURKBTEKKDR
SCHEMBL14602748 0.77 AURKA (1.00) EGFRAURKAAURKBTEKKDR
SCHEMBL5258198 0.77 EGFR (1.00) EGFRAURKAAURKBTEKKDR
SCHEMBL15454599 0.76 MAPT (0.72) EGFRMAPTMEN1ALDH1A1KMT2A
SCHEMBL12157485 0.76 MAPT (0.56) EGFRAURKAAURKBMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 EGFR 1301/4885AURKA 493/4885AURKB 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.